Academic Content and Language Evaluation of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (8157)
All Articles published online
|
Publishing Process of This Article
|
Nov 7, 2014 (publication date) through Apr 25, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Abenavoli L, Masarone M, Peta V, Milic N, Kobyliak N, Rouabhia S, Persico M. Insulin resistance and liver steatosis in chronic hepatitis C infection genotype 3. World J Gastroenterol 2014; 20(41): 15233-15240 [PMID: 25386071 DOI: 10.3748/wjg.v20.i41.15233] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v20/i41/15233.htm |
| Number | Citing Articles |
| 1 |
Dina G. Tiniakos, Quentin M. Anstee, Alastair D. Burt. Macsween's Pathology of the Liver. 2018; : 308 doi: 10.1016/B978-0-7020-6697-9.00005-4
|
| 2 |
Ratna B. Ray, Ranjit Ray. Hepatitis C Virus Manipulates Humans as its Favorite Host for a Long‐Term Relationship. Hepatology 2019; 69(2): 889 doi: 10.1002/hep.30214
|
| 3 |
Youpeng Wang, Ziyin Zhao, Tingting Guo, Tiansong Wu, Mao Zhang, Dingan Luo, Kunpeng Dou, Yeni Yang, Cheng Jin, Bingyuan Zhang, Bin Zhang, Bing Han. SOCS5-RBMX stimulates SREBP1-mediated lipogenesis to promote metastasis in steatotic HCC with HBV-related cirrhosis. npj Precision Oncology 2024; 8(1) doi: 10.1038/s41698-024-00545-6
|
| 4 |
Valeriy V. Tsvetkov, Ivan I. Tokin, Olesya E. Nikitina, Dmitry A. Lioznov. Disorders of lipid metabolism in the liver in patients with chronic viral hepatitis. HERALD of North-Western State Medical University named after I.I. Mechnikov 2021; 13(2): 27 doi: 10.17816/mechnikov71418
|
| 5 |
Marian-Sorin Popescu, Andrei Ioan Drocas, Andrei Osman, Dan-Mihai Firu, Vlad Pădureanu, Cristina Maria Mărginean, Daniel-Cristian Pîrvu, Radu Mitruț, Dragoș Nicolae Mărgăritescu, Antonia Radu, Daniela Calina, Anca Oana Docea, Paul Mitruț. The Extent of Insulin Resistance in Patients That Cleared Viral Hepatitis C Infection and the Role of Pre-Existent Type 2 Diabetes Mellitus: A Meta-Analysis. Reports 2022; 5(4): 42 doi: 10.3390/reports5040042
|
| 6 |
Hsuan-Yu Hung, Hui-Hsiung Lai, Hui-Chuan Lin, Chung-Yu Chen. The impact of sofosbuvir/velpatasvir/voxilaprevir treatment on serum hyperglycemia in hepatitis C virus infections: a systematic review and meta-analysis. Annals of Medicine 2023; 55(1): 463 doi: 10.1080/07853890.2023.2168745
|
| 7 |
Rafael Käser, Tobias Böttler. Nicht-alkoholische Fettlebererkrankung. 2022; : 301 doi: 10.1007/978-3-662-62484-5_26
|
| 8 |
Sylvia Drazilova, Jakub Gazda, Martin Janicko, Peter Jarcuska. Chronic Hepatitis C Association with Diabetes Mellitus and Cardiovascular Risk in the Era of DAA Therapy. Canadian Journal of Gastroenterology and Hepatology 2018; 2018: 1 doi: 10.1155/2018/6150861
|
| 9 |
David P. Durham, Laura A. Skrip, Robert Douglas Bruce, Silvia Vilarinho, Elamin H. Elbasha, Alison P. Galvani, Jeffrey P. Townsend. The Impact of Enhanced Screening and Treatment on Hepatitis C in the United States. Clinical Infectious Diseases 2016; 62(3): 298 doi: 10.1093/cid/civ894
|
| 10 |
N. Urganci, D. Kalyoncu, S. Geylani-Gulec. Insulin resistance in children with chronic hepatitis C and its association with response to IFN-alpha and ribavirin. Revista de Gastroenterología de México (English Edition) 2021; 86(2): 140 doi: 10.1016/j.rgmxen.2020.07.006
|
| 11 |
Chia‐Chi Wang, Pin‐Nan Cheng, Jia‐Horng Kao. Systematic review: chronic viral hepatitis and metabolic derangement. Alimentary Pharmacology & Therapeutics 2020; 51(2): 216 doi: 10.1111/apt.15575
|
| 12 |
Carolin Lackner. Practical Hepatic Pathology: a Diagnostic Approach. 2018; : 167 doi: 10.1016/B978-0-323-42873-6.00012-3
|
| 13 |
Maja Ružić, Rinaldo Pellicano, Milotka Fabri, Francesco Luzza, Luigi Boccuto, Snežana Brkić, Ludovico Abenavoli. Hepatitis C virus-induced hepatocellular carcinoma: a narrative review. Panminerva Medica 2018; 60(4) doi: 10.23736/S0031-0808.18.03472-9
|
| 14 |
Simona Ruta, Costin Cernescu. Injecting drug use: A vector for the introduction of new hepatitis C virus genotypes. World Journal of Gastroenterology 2015; 21(38): 10811-10823 doi: 10.3748/wjg.v21.i38.10811
|
| 15 |
Susanna Naggie, Andrew J. Muir. Oral Combination Therapies for Hepatitis C Virus Infection: Successes, Challenges, and Unmet Needs. Annual Review of Medicine 2017; 68(1): 345 doi: 10.1146/annurev-med-052915-015720
|
| 16 |
Lohanna STRAUHS-NITSCH, Marcela Ferro CAMPIOLO, Daphne Benatti Gonçalves MORSOLETTO, Alcindo PISSAIA JUNIOR, Claudia Alexandre Pontes IVANTES. CURING HEPATITIS C WITH THE NEW DIRECT ACTING ANTIVIRALS DID NOT IMPROVE INSULIN RESISTANCE AFTER ONE YEAR. Arquivos de Gastroenterologia 2020; 57(3): 267 doi: 10.1590/s0004-2803.202000000-50
|
| 17 |
Jee-Fu Huang, Chung-Feng Huang, Ming-Lun Yeh, Chia-Yen Dai, Ming-Lung Yu, Wan-Long Chuang. Updates in the management and treatment of HCV genotype 3, what are the remaining challenges?. Expert Review of Anti-infective Therapy 2018; 16(12): 907 doi: 10.1080/14787210.2018.1544492
|
| 18 |
Dina G. Tiniakos, Stratigoula Sakellariou. Non-Alcoholic Fatty Liver Disease. 2020; : 25 doi: 10.1007/978-3-319-95828-6_3
|
| 19 |
I. Leshchenko, O. Virchenko, O. Gadiliya, T. Falalyeyeva, L. Lazarenko. Сarbohydrate metabolism parameters under the glutamate-induced obesity in rats and concominant correction with probiotic strains of lactobacilli and bifidobacteria. Bulletin of Taras Shevchenko National University of Kyiv. Series: Biology 2015; 70(2): 20 doi: 10.17721/1728_2748.2015.70.20-23
|
| 20 |
T. Revuelto Artigas, N. Zaragoza Velasco, X. Gómez Arbones, T. Vidal Ballester, C. Piñol Felis, J.M. Reñe Espinet, A. Betriu Bars. Infección crónica por el virus de la hepatitis C: un factor de riesgo independiente para la ateromatosis subclínica. Revista Clínica Española 2019; 219(6): 293 doi: 10.1016/j.rce.2018.12.007
|
| 21 |
J. F. Waring, E. O. Dumas, S. Abel, E. Coakley, D. E. Cohen, J. Wade Davis, T. Podsadecki, S. Dutta. Serum miR‐122 may serve as a biomarker for response to direct acting antivirals: effect of paritaprevir/R with dasabuvir or ombitasvir on miR‐122 in HCV‐infected subjects. Journal of Viral Hepatitis 2016; 23(2): 96 doi: 10.1111/jvh.12470
|
| 22 |
Mazen Noureddin, Micaela M Wong, Tsuyoshi Todo, Shelly C Lu, Arun J Sanyal, Edward A Mena. Fatty liver in hepatitis C patients post-sustained virological response with direct-acting antivirals. World Journal of Gastroenterology 2018; 24(11): 1269-1277 doi: 10.3748/wjg.v24.i11.1269
|
| 23 |
T. Revuelto Artigas, N. Zaragoza Velasco, X. Gómez Arbones, T. Vidal Ballester, C. Piñol Felis, J.M. Reñe Espinet, A. Betriu Bars. Chronic hepatitis C infection: An independent risk factor for subclinical atheromatosis. Revista Clínica Española (English Edition) 2019; 219(6): 293 doi: 10.1016/j.rceng.2019.02.008
|
| 24 |
Chung-Feng Huang, Jyh-Jou Chen, Ming-Lun Yeh, Ching-I Huang, Ming-Yen Hsieh, Hua-Ling Yang, Chia-Yen Dai, Jee-Fu Huang, Zu-Yau Lin, Shinn-Cherng Chen, Wan-Long Chuang, Yao-Li Chen, Ming-Lung Yu. PNPLA3 genetic variants determine hepatic steatosis in non-obese chronic hepatitis C patients. Scientific Reports 2015; 5(1) doi: 10.1038/srep11901
|
| 25 |
Ana Claudia Silva Braga, Bruno Moreira Carneiro, Mariana Nogueira Batista, Mônica Mayumi Akinaga, Cíntia Bittar, Paula Rahal, Ratna B. Ray. Heat shock proteins HSPB8 and DNAJC5B have HCV antiviral activity. PLOS ONE 2017; 12(11): e0188467 doi: 10.1371/journal.pone.0188467
|
| 26 |
Fabrizio Angius, Angela Ingianni, Raffaello Pompei. Human Herpesvirus 8 and Host-Cell Interaction: Long-Lasting Physiological Modifications, Inflammation and Related Chronic Diseases. Microorganisms 2020; 8(3): 388 doi: 10.3390/microorganisms8030388
|
| 27 |
Sergio Ferra-Murcia, Antonio Ramón Collado-Romacho, Bruno José Nievas-Soriano, Fernando Reche-Lorite, Tesifón Parrón-Carreño. Real-Life Early Anthropometric, Lipid and Liver Changes after Direct-Acting Antiviral Therapy in PLWHIV with HCV Co-Infection. Journal of Clinical Medicine 2022; 11(9): 2639 doi: 10.3390/jcm11092639
|
| 28 |
Renata D. Giustina, Maíra L. Marconcini, Emilia T.O. Bansho, Débora Tonon, Ana P.B.F. Pasinato, Esther B. Dantas-Corrêa, Leonardo L. Schiavon, Janaína L. Narciso-Schiavon. Factors associated with steatosis in liver biopsies of individuals with chronic hepatitis C infection in southern Brazil. Arab Journal of Gastroenterology 2015; 16(2): 59 doi: 10.1016/j.ajg.2015.06.002
|
| 29 |
K V Zhdanov, S S Karyakin, K V Kozlov, D A Gusev, V S Sukachev, A V Saulevich, M V Yaremenko, S N Kizhlo, D M Shahmanov, D Yu Lobzin, M V Kurtukov, M A Dzheriev. Chronic hepatitis С and non-alcoholic fatty liver disease. Main aspects of pathogenesis. Bulletin of the Russian Military Medical Academy 2018; 20(1): 216 doi: 10.17816/brmma12326
|
| 30 |
Samarth S. Patel, Eiman Nabi, Luis Guzman, Antonio Abbate, Chandra Bhati, Richard T. Stravitz, Trevor Reichman, Scott C. Matherly, Carolyn Driscoll, Hannah Lee, Velimir A. Luketic, Richard K. Sterling, Arun J. Sanyal, Vaishali Patel, Marlon Levy, Mohammad Shadab Siddiqui. Coronary artery disease in decompensated patients undergoing liver transplantation evaluation. Liver Transplantation 2018; 24(3): 333 doi: 10.1002/lt.25012
|
| 31 |
P. O. Bogomolov, A. O. Bueverov, E. A. Fedosina, V. E. Bakirova, S. V. Koblov. Clinical parallels and experience of antivira l therapy in chronic hepatitis with polycystic ovary syndrome. Experimental and Clinical Gastroenterology 2020; 174(2): 71 doi: 10.31146/1682-8658-ecg-174-2-71-79
|
| 32 |
Yun-Cheng Hsieh, Kuei-Chuan Lee, Chien-Wei Su, Ken-Hsin Lan, Teh-Ia Huo, Yuan-Jen Wang, Hui-Chun Huang, Han-Chieh Lin, Chi-Jen Chu, Yi-Hsiang Huang, Ming-Chih Hou. Persistent liver inflammation in chronic hepatitis C patients with advanced fibrosis after direct-acting antivirals induced sustained virological response. Journal of the Chinese Medical Association 2021; 84(5): 472 doi: 10.1097/JCMA.0000000000000517
|
| 33 |
N. Urganci, D. Kalyoncu, S. Geylani-Gulec. Resistencia a la insulina en niños con hepatitis C crónica y su asociación con la respuesta al IFN-alfa y ribavirina. Revista de Gastroenterología de México 2021; 86(2): 140 doi: 10.1016/j.rgmx.2020.07.002
|
| 34 |
Hilla Knobler, Stephen Malnick. Hepatitis C and insulin action: An intimate relationship. World Journal of Hepatology 2016; 8(2): 131-138 doi: 10.4254/wjh.v8.i2.131
|
| 35 |
Austin Chan, Keyur Patel, Susanna Naggie. Genotype 3 Infection: The Last Stand of Hepatitis C Virus. Drugs 2017; 77(2): 131 doi: 10.1007/s40265-016-0685-x
|
| 36 |
Elisabeth M. Haberl, Thomas S. Weiss, Georg Peschel, Kilian Weigand, Nikolai Köhler, Josch K. Pauling, Jürgen J. Wenzel, Marcus Höring, Sabrina Krautbauer, Gerhard Liebisch, Christa Buechler. Liver Lipids of Patients with Hepatitis B and C and Associated Hepatocellular Carcinoma. International Journal of Molecular Sciences 2021; 22(10): 5297 doi: 10.3390/ijms22105297
|
| 37 |
Moris Sangineto, Rosanna Villani, Francesco Cavallone, Antonino Romano, Domenico Loizzi, Gaetano Serviddio. Lipid Metabolism in Development and Progression of Hepatocellular Carcinoma. Cancers 2020; 12(6): 1419 doi: 10.3390/cancers12061419
|
| 38 |
Zobair M. Younossi, Maria Stepanova, Mark Sulkowski, Graham R. Foster, Nancy Reau, Alessandra Mangia, Keyur Patel, Norbert Bräu, Stuart K. Roberts, Nezam Afdhal, Fatema Nader, Linda Henry, Sharon Hunt. Ribavirin-Free Regimen With Sofosbuvir and Velpatasvir Is Associated With High Efficacy and Improvement of Patient-Reported Outcomes in Patients With Genotypes 2 and 3 Chronic Hepatitis C: Results From Astral-2 and -3 Clinical Trials. Clinical Infectious Diseases 2016; 63(8): 1042 doi: 10.1093/cid/ciw496
|
| 39 |
Kumari Anuja, Souvick Roy, Chinmoy Ghosh, Priya Gupta, Surajit Bhattacharjee, Birendranath Banerjee. Prolonged inflammatory microenvironment is crucial for pro-neoplastic growth and genome instability: a detailed review. Inflammation Research 2017; 66(2): 119 doi: 10.1007/s00011-016-0985-3
|
| 40 |
Fabrizio Angius, Luisa Marras, Angela Ingianni, Raffaello Pompei. Emerging and Reemerging Viral Pathogens. 2020; : 169 doi: 10.1016/B978-0-12-819400-3.00009-0
|
| 41 |
Uday Kumar Marri, Kumble Seetharama Madhusudhan. Dual-Energy Computed Tomography in Diffuse Liver Diseases. Journal of Gastrointestinal and Abdominal Radiology 2022; 5(02): 094 doi: 10.1055/s-0042-1742432
|
| 42 |
Daniela Gabbia, Marco Roverso, Samantha Sarcognato, Ilaria Zanotto, Nicola Ferri, Francesco Paolo Russo, Maria Guido, Sara Bogialli, Sara De Martin. The Metabolic Activation of Sofosbuvir Is Impaired in an Experimental Model of NAFLD. Biology 2022; 11(5): 693 doi: 10.3390/biology11050693
|
| 43 |
Dina G. Tiniakos, Quentin M. Anstee, Elizabeth M. Brunt, Alastair D. Burt. MacSween's Pathology of the Liver. 2024; : 330 doi: 10.1016/B978-0-7020-8228-3.00005-3
|
| 44 |
Jinhong Ren, Isabel Ojeda, Maulik Patel, Michael E. Johnson, Hyun Lee. Exploring small molecules with pan-genotypic inhibitory activities against hepatitis C virus NS3/4A serine protease. Bioorganic & Medicinal Chemistry Letters 2019; 29(16): 2349 doi: 10.1016/j.bmcl.2019.06.009
|
| 45 |
Tien S Dong, Elizabeth S Aby, Jihane N Benhammou, Jenna Kawamoto, Steven-Huy Han, Folasade P May, Joseph R Pisegna. Metabolic syndrome does not affect sustained virologic response of direct-acting antivirals while hepatitis C clearance improves hemoglobin A1c. World Journal of Hepatology 2018; 10(9): 612-621 doi: 10.4254/wjh.v10.i9.612
|
| 46 |
Megan C. Jacobsen, Sara L. Thrower, Rachel B. Ger, Shuai Leng, Laurence E. Court, Kristy K. Brock, Eric P. Tamm, Erik N.K. Cressman, Dianna D. Cody, Rick R. Layman. Multi‐energy computed tomography and material quantification: Current barriers and opportunities for advancement. Medical Physics 2020; 47(8): 3752 doi: 10.1002/mp.14241
|
| 47 |
Monika Rau, Peter Buggisch, Stefan Mauss, Klaus H. W. Boeker, Hartwig Klinker, Tobias Müller, Albrecht Stoehr, Jörn M. Schattenberg, Andreas Geier, Pavel Strnad. Prognostic impact of steatosis in the clinical course of chronic HCV infection—Results from the German Hepatitis C-Registry. PLOS ONE 2022; 17(6): e0264741 doi: 10.1371/journal.pone.0264741
|
| 48 |
Gautam Ray. Factors affecting outcome of treatment of chronic hepatitis C: result of an open label study from eastern India. Tropical Doctor 2016; 46(1): 28 doi: 10.1177/0049475515569519
|
| 49 |
Vladimir Alexei Morozov, Sylvie Lagaye. Hepatitis C virus: Morphogenesis, infection and therapy. World Journal of Hepatology 2018; 10(2): 186-212 doi: 10.4254/wjh.v10.i2.186
|
| 50 |
Reza Taherkhani, Fatemeh Farshadpour. Epidemiology of hepatitis C virus in Iran. World Journal of Gastroenterology 2015; 21(38): 10790-10810 doi: 10.3748/wjg.v21.i38.10790
|
| 51 |
Sanjaya K. Satapathy, Vanessa Kuwajima, Jeffrey Nadelson, Omair Atiq, Arun J. Sanyal. Drug-induced fatty liver disease: An overview of pathogenesis and management. Annals of Hepatology 2015; 14(6): 789 doi: 10.5604/16652681.1171749
|